Lineage Cell Therapeutics Inc (NYSE American:LCTX)
| 0.9509 Delayed Data As of 3:49pm ET |  -0.0175 / -1.81%Today’s Change | 0.93 Today|||52-Week Range 1.58 | -18.73% Year-to-Date |
Latest LCTX News | Press Releases
No recent news for Lineage Cell Therapeutics Inc.
Today’s Trading
| Previous close | 0.97 |
| Today’s open | 0.95 |
| Day’s range | 0.95 - 0.98 |
| Volume | 560,659 |
| Average volume (3 months) | 445,028 |
| Market cap | $171.6M |
Data as of 3:49pm ET, 11/28/2023
Growth & Valuation
| Earnings growth (last year) | +40.84% |
| Earnings growth (this year) | -16.19% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +277.39% |
| P/E ratio | NM |
| Price/Sales | 13.51 |
| Price/Book | 2.27 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| VSTMVerastem Inc | -0.22 | -3.36% |
| HARPHarpoon Therapeutics... | +0.74 | +7.60% |
| RIGLRigel Pharmaceutical... | +0.05 | +5.05% |
| XOMAXOMA Corp | +0.14 | +0.94% |
Data as of 3:59pm ET, 11/28/2023
Financials
| Next reporting date | March 14, 2024 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $14.7M |
| Annual profit (last year) | -$26.3M |
| Net profit margin | -178.69% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Carlsbad, California |
Forecasts
